AI-generated analysis. Always verify with the original filing.
Basel Medical Group Ltd reported a net loss of US$8.36 million (S$10.64 million) for FY2025, a significant decline from a net profit of S$2.07 million in FY2024. This loss was primarily driven by a US$8.14 million (S$10.35 million) impairment loss on goodwill related to the acquisition of Bethesda Medical Pte Ltd. Revenue increased by 12.6% to US$8.90 million (S$11.32 million), attributed to contributions from the newly acquired Bethesda general practice clinics (S$0.90 million) and a 3.7% increase in the orthopedic specialist clinic revenue. The company's cash position improved to US$2.39 million (S$3.04 million) as of June 30, 2025, from US$1.53 million (S$1.95 million) the prior year, supported by net proceeds from its initial public offering. The company is an emerging growth company and a foreign private issuer listed on Nasdaq.
EPS
US$-0.45
Revenue
US$8.90M
Net Income
US$-8.36M
total assets
US$14.69M
total equity
US$4.28M
cash and cash equivalents
US$2.39M